These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1916 related articles for article (PubMed ID: 33643299)

  • 21. Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies.
    Zhang ZZ; Wang T; Wang XF; Zhang YQ; Song SX; Ma CQ
    Pharmacol Res; 2022 Jan; 175():106036. PubMed ID: 34920118
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
    Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
    Front Immunol; 2020; 11():564099. PubMed ID: 33329526
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies.
    Liu Y; Peng C; Ahad F; Ali Zaidi SA; Muluh TA; Fu Q
    Recent Pat Anticancer Drug Discov; 2024; 19(5):557-572. PubMed ID: 38213150
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Critical care management of chimeric antigen receptor T-cell therapy recipients.
    Shimabukuro-Vornhagen A; Böll B; Schellongowski P; Valade S; Metaxa V; Azoulay E; von Bergwelt-Baildon M
    CA Cancer J Clin; 2022 Jan; 72(1):78-93. PubMed ID: 34613616
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions.
    Bagley SJ; O'Rourke DM
    Pharmacol Ther; 2020 Jan; 205():107419. PubMed ID: 31629009
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel treatment strategies for hematological malignancies in the immunotherapy era.
    Imai Y
    Int J Hematol; 2024 Jul; 120(1):3-5. PubMed ID: 38861242
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment.
    Yan Z; Zhang H; Cao J; Zhang C; Liu H; Huang H; Cheng H; Qiao J; Wang Y; Wang Y; Gao L; Shi M; Sang W; Zhu F; Li D; Sun H; Wu Q; Qi Y; Li H; Wang X; Li Z; Liu H; Zheng J; Qian W; Zhang X; Xu K
    Front Immunol; 2021; 12():611366. PubMed ID: 33708205
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Future perspectives on engineered T cells for cancer.
    Posey AD; Young RM; June CH
    Trends Cancer; 2024 Aug; 10(8):687-695. PubMed ID: 38853073
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
    Pehlivan KC; Duncan BB; Lee DW
    Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy.
    Ti D; Niu Y; Wu Z; Fu X; Han W
    Sci China Life Sci; 2018 Nov; 61(11):1320-1332. PubMed ID: 30414005
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions.
    Zhang P; Zhang Y; Ji N
    Front Immunol; 2022; 13():927132. PubMed ID: 35874698
    [TBL] [Abstract][Full Text] [Related]  

  • 33. JAK/STAT-Dependent Chimeric Antigen Receptor (CAR) Expression: A Design Benefiting From a Dual AND/OR Gate Aiming to Increase Specificity, Reduce Tumor Escape and Affect Tumor Microenvironment.
    Khanali J; Azangou-Khyavy M; Boroomand-Saboor M; Ghasemi M; Niknejad H
    Front Immunol; 2021; 12():638639. PubMed ID: 34177890
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success.
    Long KB; Young RM; Boesteanu AC; Davis MM; Melenhorst JJ; Lacey SF; DeGaramo DA; Levine BL; Fraietta JA
    Front Immunol; 2018; 9():2740. PubMed ID: 30559740
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic potential of CAR T cell in malignancies: A scoping review.
    Mehrabadi AZ; Ranjbar R; Farzanehpour M; Shahriary A; Dorostkar R; Hamidinejad MA; Ghaleh HEG
    Biomed Pharmacother; 2022 Feb; 146():112512. PubMed ID: 34894519
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CAR T-Cell Therapy in Hematologic Malignancies: A Voyage in Progress.
    Holstein SA; Lunning MA
    Clin Pharmacol Ther; 2020 Jan; 107(1):112-122. PubMed ID: 31622496
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advancements in Personalized CAR-T Therapy: Comprehensive Overview of Biomarkers and Therapeutic Targets in Hematological Malignancies.
    Olejarz W; Sadowski K; Szulczyk D; Basak G
    Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39062986
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T Cell Exhaustion and CAR-T Immunotherapy in Hematological Malignancies.
    Tang L; Zhang Y; Hu Y; Mei H
    Biomed Res Int; 2021; 2021():6616391. PubMed ID: 33728333
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial.
    Narayan V; Barber-Rotenberg JS; Jung IY; Lacey SF; Rech AJ; Davis MM; Hwang WT; Lal P; Carpenter EL; Maude SL; Plesa G; Vapiwala N; Chew A; Moniak M; Sebro RA; Farwell MD; Marshall A; Gilmore J; Lledo L; Dengel K; Church SE; Hether TD; Xu J; Gohil M; Buckingham TH; Yee SS; Gonzalez VE; Kulikovskaya I; Chen F; Tian L; Tien K; Gladney W; Nobles CL; Raymond HE; ; Hexner EO; Siegel DL; Bushman FD; June CH; Fraietta JA; Haas NB
    Nat Med; 2022 Apr; 28(4):724-734. PubMed ID: 35314843
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy.
    Rodriguez-Garcia A; Lynn RC; Poussin M; Eiva MA; Shaw LC; O'Connor RS; Minutolo NG; Casado-Medrano V; Lopez G; Matsuyama T; Powell DJ
    Nat Commun; 2021 Feb; 12(1):877. PubMed ID: 33563975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 96.